Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation.
Thomenius, M.J., Totman, J., Harvey, D., Mitchell, L.H., Riera, T.V., Cosmopoulos, K., Grassian, A.R., Klaus, C., Foley, M., Admirand, E.A., Jahic, H., Majer, C., Wigle, T., Jacques, S.L., Gureasko, J., Brach, D., Lingaraj, T., West, K., Smith, S., Rioux, N., Waters, N.J., Tang, C., Raimondi, A., Munchhof, M., Mills, J.E., Ribich, S., Porter Scott, M., Kuntz, K.W., Janzen, W.P., Moyer, M., Smith, J.J., Chesworth, R., Copeland, R.A., Boriack-Sjodin, P.A.
Plos One